Voorbeelden van het gebruik van Endolucinbeta in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
How is EndolucinBeta used?
Other information about EndolucinBeta.
Why is EndolucinBeta approved?
Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta.
What EndolucinBeta looks like and contents of the pack?
The carrier medicine then takes the EndolucinBeta to the disease site in the body.
EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution.
Radiolabelling with EndolucinBeta takes place in a laboratory.
EndolucinBeta is not to be administered directly to patients.
Information on how to minimise the risks is included in the product information for EndolucinBeta.
EndolucinBeta is never given to a patient on its own.
Therefore, Lutetium metal- ion toxicity of EndolucinBeta(177Lu)-labelled medicinal products can be excluded.
EndolucinBeta is a radiopharmaceutical precursor, solution.
The volume depends on the quantity of medicine combined with EndolucinBeta required for administration by the nuclear medicine doctor.
EndolucinBeta is not a medicine
Take special care with the medicine that is radiolabelled with EndolucinBeta: if you have renal impairment or bone marrow disease.
EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution Lutetium(177Lu) chloride.
The CHMP concluded that the benefits of EndolucinBeta outweigh the risks
EndolucinBeta is only used by specialists who have experience in radiolabelling.
The following preparations must be available in medical institutions, which use EndolucinBeta for labelling of carrier molecules for therapeutic purposes.
EndolucinBeta will be stored in the original package that provides protection from radiation.
Information on restrictions that apply specifically to medicines radiolabelled with EndolucinBeta can be found in the package leaflets of those medicines.
EndolucinBeta is not to be used directly in childrens and adolescent patients under 18 years old.
Adequate quality control of the radiochemical purity of ready to use radiopharmaceuticals gained after radiolabelling with EndolucinBeta should be assured.
EndolucinBeta is only to be used by specialists experienced with in vitro radiolabelling.
However, the quantity of EndolucinBeta to be used is very small
EndolucinBeta is a radiopharmaceutical precursor,
The benefits of EndolucinBeta will largely depend on the medicine that it is used to radiolabel.
EndolucinBeta has to be combined with a carrier medicine in a process called radiolabelling before administration.
EndolucinBeta contains the radioactive compound lutetium(177Lu)
